AI assistant
Sending…
Silence Therapeutics plc — Director's Dealing 2025
Apr 24, 2025
33536_dirs_2025-04-24_45076ccb-54c7-4500-82aa-ad625f51e7eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Silence Therapeutics plc (SLN)
CIK: 0001479615
Period of Report: 2025-04-22
Reporting Person: Griffiths Richard Ian (10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-22 | American Depositary Shares | $3.10 | P | 50000 | Acquired | Ordinary Shares (150000) | Direct | |
| 2025-04-23 | American Depositary Shares | $3.18 | P | 50000 | Acquired | Ordinary Shares (150000) | Direct |
Footnotes
F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.
More from Silence Therapeutics plc
Capital/Financing Update
2026
May 27
Capital/Financing Update
2026
May 18
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Proxy Solicitation & Information Statement
2026
Apr 29
Director's Dealing
2026
Feb 13
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6